Skip to main content
SpringerLink
Log in

Managing Psychiatric Disorders in Athletes

  • Chapter
  • First Online:
Mental Health in the Athlete

Abstract

Pharmacotherapy is an important psychiatric tool available to treat mental illness in athletes. There are at least three important, unique considerations when prescribing a psychiatric medication to an athlete: (1) potential negative impact on athletic performance; (2) potential performance-enhancing effects; and (3) potential safety risks. Furthermore, there are unique considerations within each category of psychiatric medications when it comes to prescribing for athletes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bauman NJ. The stigma of mental health in athletes: are mental toughness and mental health seen as contradictory in elite sport? Br J Sports Med. 2016;50(3):135–6.

    Article  PubMed  Google Scholar 

  2. Reardon CL, Creado S. Psychiatric medication preferences of sports psychiatrists. Phys Sportsmed. 2016;44(4):397–402.

    Article  PubMed  Google Scholar 

  3. NCAA Sport Science Institute. 2017–2018 NCAA Banned Drugs List [Internet]. Indianapolis, IN: The National Collegiate Athletic Association; 2017. Available from: http://www.ncaa.org/2017-18-ncaa-banned-drugs-list.

  4. World Anti-Doping Agency. Prohibited List [Internet]. Quebec, Montreal: World Anti-Doping Agency; 2018. Available from: https://www.wada-ama.org/sites/default/files/prohibited_list_2018_en.pdf

  5. de Zwaan M. Exercise and antidepressant serum levels. Biol Psychiatry. 1992;32:210–1.

    Article  PubMed  Google Scholar 

  6. Reardon CL, Factor RM. Sport psychiatry: a systematic review of diagnosis and medical treatment of mental illness in athletes. Sports Med. 2010;40(11):961–80.

    Article  PubMed  Google Scholar 

  7. World Anti-Doping Agency. Monitoring Program [Internet]. Quebec, Montreal: World Anti-Doping Agency; 2018. Available from: https://www.wada-ama.org/en/resources/science-medicine/monitoring-program

  8. Watson P, Hasegawa H, Roelands B, Piacentini MF, Looverie R, Meeusen R. Acute dopamine/noradrenaline reuptake inhibition enhances human exercise performance in warm, but not temperate conditions. J Physiol. 2005;565(3):873–83.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Roelands B, Hasegawa H, Watson P, Piacentini MF, Buyse L, De Schutter G, et al. Performance and thermoregulatory effects of chronic bupropion administration in the heat. Eur J Appl Physiol. 2009;105(3):493–8.

    Article  PubMed  Google Scholar 

  10. Roelands B, Watson P, Cordery P, Decoster S, Debaste E, Maughan R, et al. A dopamine/noradrenaline reuptake inhibitor improves performance in the heat, but only at the maximum therapeutic dose. Scand J Med Sci Sports. 2012;22(5):e93–8.

    Article  PubMed  Google Scholar 

  11. Parise G, Bosman MJ, Boeeker DR. Selective serotonin reuptake inhibitors: their effect on high-intensity exercise performance. Arch Phys Med Rehabil. 2001;82:867–71.

    Article  PubMed  Google Scholar 

  12. Meeusen R, Piacentini MF, van Den Eynde S, Magnus L, De Meirleir K. Exercise performance is not influenced by a 5-HT reuptake inhibitor. Int J Sports Med. 2001;22:329–36.

    Article  PubMed  Google Scholar 

  13. Baum AL. Psychopharmacology in athletes. In: Begel D, Burton RW, editors. Sport psychiatry. New York, NY: WW Norton & Company; 2000. p. 249–59.

    Google Scholar 

  14. Reardon CL. The sports psychiatrist and psychiatric medications. Int Rev Psychiatry. 2016;28(6):606–13.

    Article  PubMed  Google Scholar 

  15. Marvin G, Sharma A, Aston W, Field C, Kendall MJ, Jones DA. The effects of buspirone on perceived exertion and time to fatigue in man. Exp Physiol. 1997;82:1057–60.

    Article  PubMed  Google Scholar 

  16. Paul MA, Gray G, Kenny G, Pigeau RA. Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Aviat Space Environ Med. 2003;74(12):1263–70.

    PubMed  Google Scholar 

  17. Charles RB, Kirkham AJ, Guyatt AR, Parker SP. Psychomotor, pulmonary and exercise responses to sleep medication. Br J Clin Pharm. 1987;24:191–7.

    Article  Google Scholar 

  18. Cowan DA. Drug abuse. In: Harries M, Williams C, Stanish WD, Micheli LJ, editors. Oxford textbook of sports medicine. New York, NY: Oxford University Press; 1994. p. 314–29.

    Google Scholar 

  19. Atkinson G, Drust B, Reilly T, Waterhouse J. The relevance of melatonin to sports medicine and science. Sports Med. 2003;33(11):809–31.

    Article  PubMed  Google Scholar 

  20. Herman D, Macknight JM, Stromwall AE, Mistry DJ. The international athlete—advances in management of jet lag and anti-doping policy. Clin Sports Med. 2011;30(3):641–59.

    Article  PubMed  Google Scholar 

  21. Ito SU, Kanbayashi T, Takemura T, Kondo H, Inomata S, Szilagyi G, et al. Acute effects of zolpidem on daytime alertness, psychomotor and physical performance. Neurosci Res. 2007;59:309–13.

    Article  PubMed  Google Scholar 

  22. Grobler LA, Schwellnus MP, Trichard C, Calder S, Noakes TD, Derman WE. Comparative effects of zopiclone and loprazolam on psychomotor and physical performance in active individuals. Clin J Sport Med. 2000;10(2):123–8.

    Article  PubMed  Google Scholar 

  23. Tafti M, Besset A, Billiard M. Effects of zopiclone on subjective evaluation of sleep and daytime alertness and on psychomotor and physical performance tests in athletes. Prog Neuro-Psychopharmacol Biol Psychiatry. 1992;16:55–63.

    Article  Google Scholar 

  24. Holmberg G. The effects of anxiolytics on CFF. Pharmacopsychiatry. 1982;15 Suppl:49–53.

    Article  Google Scholar 

  25. Maddock RJ, Casson EJ, Lott LA, Carter CS, Johnson CA. Benzodiazepine effects on flicker sensitivity: role of stimulus frequency and size. Prog Neuro-Psychopharmacol Biol Psychiatry. 1993;17:955–70.

    Article  Google Scholar 

  26. Chandler JV, Blair SN. The effect of amphetamines on selected physiological components related to athletic success. Med Sci Sports Exerc. 1980;12(1):65–9.

    Article  PubMed  Google Scholar 

  27. Roelands B, Hasegawa H, Watson P, Piacentini MF, Buyse L, De Schutter G, et al. The effects of acute dopamine reuptake inhibition on performance. Med Sci Sports Exerc. 2008;40(5):879–85.

    Article  PubMed  Google Scholar 

  28. NCAA Sport Science Institute. Drug-testing exceptions procedures [Internet]. Indianapolis, IN: The National Collegiate Athletic Association; 2017. Available from: http://www.ncaa.org/health-and-safety/sport-science-institute/drug-testing-exceptions-procedures

  29. World Anti-Doping Agency. Therapeutic use exemptions [Internet]. Quebec, Montreal: World Anti-Doping Agency; 2018. Available from: https://www.wada-ama.org/en/what-we-do/science-medical/therapeutic-use-exemptions

  30. U.S. Anti-Doping Agency. Apply for a therapeutic use exemption (TUE) [Internet]. Colorado Springs, CO: U.S. Anti-Doping Agency; 2014. Available from: https://www.usada.org/substances/tue/apply/

  31. Reardon CL, Factor RM. Considerations in the use of stimulants in sport. Sports Med. 2016;46(5):611–7.

    Article  PubMed  Google Scholar 

  32. Verbeeck W, Bekkering GE, Van den Noortgate W, Kramers C. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2017;

    Google Scholar 

  33. Joy E, Kussman A, Nattiv A. 2016 update on eating disorders in athletes: a comprehensive narrative review with a focus on clinical assessment and management. Br J Sports Med. 2016;50:154–62.

    Article  PubMed  Google Scholar 

  34. American Psychiatric Association (APA). Practice guideline for the treatment of patients with eating disorders. 3rd ed. [Internet]. Washington, D.C.: American Psychiatric Association Publishing; 2010. Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/eatingdisorders.pdf

  35. Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54(1):1–13.

    Article  PubMed  Google Scholar 

  36. Macleod AD. Sport psychiatry. Aust N Z J Psychiatry. 1998;32:860–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Wisconsin School of Medicine and Public Health, Department of Psychiatry, Madison, WI, USA

    Claudia L. Reardon

Authors
  1. Claudia L. Reardon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudia L. Reardon .

Editor information

Editors and Affiliations

  1. Department of Family Medicine and Department of Orthopaedics, Medical University of South Carolina, Charleston, SC, USA

    Eugene Hong

  2. Department of Family Medicine, University of Washington, Seattle, WA, USA

    Ashwin L. Rao

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Reardon, C.L. (2020). Managing Psychiatric Disorders in Athletes. In: Hong, E., Rao, A. (eds) Mental Health in the Athlete. Springer, Cham. https://doi.org/10.1007/978-3-030-44754-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-44754-0_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-44753-3

  • Online ISBN: 978-3-030-44754-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation